Our Company l News & Events

Ikonisys awarded contract by michigan institute of urology for digital microscopy system and bladder cancer application

New Haven, CT, May 17, 2007:

Ikonisys Inc., the leading developer of automated cell-based diagnostic products, today announced the non-exclusive sale to Michigan Institute of Urology, P.C. of its proprietary Ikoniscope®robotic microscopy platform and its oncoFISH bladder application. In conjunction with the Ikoniscope, oncoFISH® bladder enables automated testing of cells found in urine specimens to aid in the detection of bladder cancer. Earlier this year, oncoFISH bladder became the first fully automated oncology diagnostic test to be cleared for marketing by the United States Food and Drug Administration (FDA). "The Ikoniscope is the only high-throughput plug-and-play system on the market, and we have found that it enables greater analytical sensitivity than any other fluorescence in situ hybridization analysis system," said Alphonse Santino, MD, President and CEO of Michigan Institute of Urology. "We are dedicated to providing our patients with the most up-to-date, quality, cost-effective urologic care available, and are pleased to integrate the Ikoniscope and the oncoFISH bladder cancer diagnostic assay into our service offerings."

"Michigan Institute of Urology is one of the oldest and the largest multi-specialty urology practices in the state of Michigan, and we are very pleased that the practice will begin using our oncoFISH bladder diagnostic test to aid in improving the sensitivity, efficiency and cost-effectiveness of making bladder cancer diagnoses," said Petros Tsipouras, M.D., Chairman and CEO of Ikonisys.

Ikonisys suite of diagnostic products automates a standard but time-consuming laboratory technique, fluorescence in situ hybridization (FISH), which identifies chromosome aberrations associated with various diseases. oncoFISH bladder detects aberrations for chromosomes 3, 7, 9, and 17 in cells found in urine sediment to aid in the initial diagnosis of bladder cancer in patients with hematuria (blood in the urine) and the subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.

About Bladder Cancer
Bladder cancer is one of the most common cancers in the United States. More than 61,000 new cases of bladder cancer were diagnosed in 2006, according to the American Cancer Society, and most patients are monitored for recurrent disease.

About Ikonisys
Ikonisys develops, commercializes and markets a digital microscopy platform and proprietary diagnostic applications that increase throughput and improve the accuracy of diagnostic screening in the areas of cancer diagnosis and management, prenatal detection of genetic disorders and fertility. The Company has developed two product lines, oncoFISH for cancer diagnostics and monitoring and fastFISH for the prenatal detection of genetic disorders, which are designed to run on the company's proprietary Ikoniscope robotic digital microscopy platform. Additional information about Ikonisys and the Company's products can be found at www.ikonisys.com.